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Background: Immunocompromised patients with influenza are at higher risk of pneumonia and
death. However, risk factors for progression to pneumonia still need evaluation.
Methods: Retrospective study in immunocompromised patients with influenza-related respira-
tory infections. Risk factors for pneumonia were identified by multivariable logistic regression.
Results: We identified 100 immunocompromised patients infected with influenza (68 hemato-
logical malignancies, 11 HIV, 21 iatrogenic immunosuppression). Immunofluorescence was posi-
tive in 95% of patients, mainly on nasopharyngeal aspirates (84%). Influenza A virus was
involved in 80% of patients. Associated infection was documented in 34 patients. All patients
presented with upper respiratory tract infection and 53 progressed to pneumonia. Thirty-two
patients were critically ill, 11 received mechanical ventilation, and 10 died. All the patients
who died had pneumonia. Patients with pneumonia were older (46y (36e63) vs. 33y (13e
51), PZ 0.003) and more often had influenza A (89% vs. 70%, PZ 0.04) and associated infec-
tion (56% vs. 9%, P< 0.0001). Factors independently associated with progression to pneumoniay distress syndrome; BAL, bronchoalveolar lavage; CI, confidence interval; CT, computed tomography;
HSCT, hematopoietic stem cell transplantation; ICU, intensive care unit; MDCK cells, MadineDarby
geal aspirates; OR, odds ratio; SAPSII, simplified acute physiologic score II; URTI, upper respiratory
oˆpital Saint-Louis, Re´animation me´dicale, 1 avenue Claude Vellefaux, 75010 Paris, France. Tel.: þ33
abc.aphp.fr (D. Schnell), julien.mayaux@sls.aphp.fr (J. Mayaux), cedric.de-bazelaire@sls.aphp.fr
sls.aphp.fr (J. Legoff), severine.feuillet@sls.aphp.fr (S. Feuillet), catherine.scieux@sls.aphp.fr
ls.aphp.fr (J. Andreu-Gallien), michael.darmon@sls.aphp.fr (M. Darmon), andre.baruchel@sls.aphp.fr
php.fr (B. Schlemmer), elie.azoulay@sls.ap-hop-paris.fr, elie.azoulay@sls.aphp.fr (E´. Azoulay).
0 Elsevier Ltd. All rights reserved.
Influenza in immunocompromised patients 1051were influenza A (OR 5.54, 95% CI [1.16e26.47]) and hematological malignancies (OR 3.85, 95%
CI [1.1e14.5]).
Conclusions: In our cohort of hospitalized immunocompromised patients, influenza progresses
to pneumonia in more than half the patients. Patients with hematological malignancies and
influenza A infection are at higher risk for pneumonia and should be included in preemptive
antiviral therapy trials.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Influenza viruses are ubiquitous respiratory pathogens that
are responsible for a high burden of disease.1 Each year,
nearly 6% of adults and 20% of children worldwide become
infected.2 Although upper respiratory tract infection (URTI)
is the usual presentation, life-threatening pneumonia
related to the virus or to bacterial or fungal superinfection
may develop. Influenza may cause severe pneumonia in
immunocompromised patients.3 Most of the immunocom-
promised patients who die with influenza have pneumo-
nia.4e7 Among patients with cancer, the introduction in
recent years of high-dose anticancer chemotherapy and
stem cell transplantation has increased the opportunities
for severe influenza.4e10 Patients infected with the Human
Immunodeficiency Virus (HIV) may be at high risk for severe
influenza.11e13 It remains unclear whether the risk of
influenza-related pneumonia is increased in other pop-
ulations of immunocompromised patients, particularly
those receiving immunosuppressive agents for connective
tissue diseases or other systemic diseases. Furthermore,
the risk factors for influenza-related pneumonia in immu-
nocompromised patients have not been studied.
The main objective of this study was to describe clinical
features and outcomes in unselected immunocompromised
patients with influenza, and to identify risk factors for
influenza-related pneumonia.
Patients and methods
We retrospectively studied immunocompromised patients
admitted to our institution with influenza between January
1998 and February 2008. Only patients with influenza
documented by immunofluorescence and/or viral culture
were included. Our institutional review board approved this
non-interventional retrospective study.
Immunocompromised status was defined as presence of
a disease (hematological malignancy, metastatic solid
tumor, or HIV infection) or treatment (long-term cortico-
steroid therapy, immunosuppressive therapy, cytotoxic
chemotherapy, and or bone marrow or hematopoietic stem
cell transplantation [HSCT]) known to impair the immune
system. Neutropenia was defined as an absolute neutrophil
count less than 500 cells/mm3.
Immunofluorescence (Imagen, DakoCytomation,
Trappes, France) was used routinely to test nasopharyngeal
aspirates (NPA) or bronchoalveolar lavage (BAL) fluid
(collected as previously described14) for influenza A and B
viruses; respiratory syncytial virus; parainfluenza viruses 1,
2, and 3; and adenoviruses. Characteristic intracellular
fluorescence indicated the presence of viral antigen withinrespiratory cells. When the specimen contained no respi-
ratory epithelial cells, the findings were considered incon-
clusive and further specimens were obtained. Viral cultures
were performed by specimen inoculation on MadineDarby
canine kidney (MDCK) cell lines until March 2006. After this
date, culture was no more available as a diagnostic tool for
influenza. Cultures were incubated for 24 hours at 37 C
and screened by immuno-peroxidase staining using mono-
clonal antibodies to influenza A and B viruses (Argene,
Varilhes, France). All patients were investigated for asso-
ciated infection. Most of them underwent noninvasive tests
to look for associated infections, such as sputum exami-
nation for bacteria, mycobacteria, and fungi; induced
sputum for Pneumocystis jiroveci pneumonia; serum and
blood tests for circulating Cytomegalovirus and Aspergillus;
and urine tests for bacterial antigens.15,16 Bronchoscopy
and BAL were performed when deemed appropriate by the
attending physician. BAL fluid was also used for viral,
bacterial, mycobacterial, and fungal cultures and for
cytological examination.
Influenza-related URTI was defined as an upper respira-
tory tract specimen positive for an influenza virus in
a patient with symptoms suggesting URTI (fever, rhinor-
rhea, nasal or sinus congestion, pharyngitis, laryngitis, and/
or cough with or without expectoration). Influenza-related
pneumonia was defined as an upper or lower respiratory
tract specimen positive for an influenza virus in a patient
with symptoms suggesting pneumonia (fever, dyspnea,
crackles, hypoxemia, and pulmonary infiltrates by chest
radiography). Microbiologically documented associated
infection was defined as recovery of a pathogenic bacterial,
fungal, or viral organism from a respiratory sample (NPA,
sputum, tracheal aspirate, or BAL fluid) in a patient with
clinical and radiological signs suggesting infection by this
pathogen and concurrent documented influenza. Clinically
documented associated infection was defined as a strong
clinical and radiographic suspicion of pneumonia without
microbiological documentation but with either septic shock
or complete resolution after antibacterial treatment in
a patient with documented influenza.14 Antiviral therapy
was left to clinician’s discretion.
Quantitative parameters are reported as median and
interquartile range (IQR, 25the75th percentiles) and qual-
itative parameters as number and percentage. Categorical
variables were compared using the c2 test or Fisher’s exact
test, as appropriate. Continuous variables were compared
using the ManneWhitney U test or the Wilcoxon test, as
appropriate. Vital status at hospital discharge was known
for all study patients. Associations between patient char-
acteristics and pneumonia were assessed using a logistic
regression model. Multivariable analysis was performed
using a stepwise forward selection procedure to introduce
1052 D. Schnell et al.variables whose P values were smaller than 0.20 by
univariate analysis. Then, the absence of a significant
increase in the likelihood value after omission of each of
the remaining variables was checked. Odds ratios (OR) and
their 95% confidence intervals (95% CI) were computed. P
values less than 0.05 were considered significant. Statistical
analyses were performed using Statview 5.0 (SAS Institute,
Cary, NC).Results
We identified 100 immunocompromised patients admitted
for documented influenza during the 10-year study period,
65 men and 35 women aged 43 (18e58) years. The under-
lying diseases are listed in Table 1. Of the 68 patients with
hematological malignancies, 34 had received HSCT (allo-
geneic in 32 and autologous in 2) and only 9 (13%) were
neutropenic at the onset of the viral disease. The 11 HIV-
infected patients had a median CD4þ count of 409 (213e
691) mm3. They all have had previous opportunistic
infections and were receiving highly active antiretroviral
therapy. The remaining 21 patients had iatrogenic immu-
nosuppression. The 12 patients on corticosteroid therapyTable 1 Causes of immune deficiency and symptoms in the 100
influenza.
To
Cause
Hematological malignancy 68
Acute lymphocytic leukemia 16
Lymphoma 11
Chronic lymphocytic leukemia 5
Acute myeloid leukemia 11
Chronic myeloid leukemia 6
Other chronic myeloproliferative disordersa 5
Myeloma 2
Othersb 12
HIV infection 11
Iatrogenic immunosuppression 21
Immunosuppressive therapyc 9
Steroid therapyd 12
Study population 10
Symptoms
Fever 88
Cough 71
Dyspnea 40
General symptomse 27
Bronchospasm 15
Gastrointestinal symptoms 11
Data are numbers (percent).
The sum of percentages for symptoms exceed 100% since most patien
a Idiopathic myelofibrosis, nZ 4; polycythemia vera, nZ 1.
b Myelodysplasia, nZ 6; Fanconi’s disease, nZ 3; and idiopathic ap
c Immunosuppressive treatments were given for renal transplantati
d Corticosteroid therapy was given for asthma (nZ 5), chronic obst
(nZ 2).
e General symptoms: asthenia, myalgia and headache.
f Nasopharyngeal aspirate as diagnostic specimen.
g Bronchoalveolar lavage fluid as diagnostic specimen.had received at least 10 mg prednisone daily for at least 4
weeks. In all patients with iatrogenic immune suppression,
immunosuppressive therapies were stopped in the first days
of infective episode until satisfactory infection control was
obtained.
The influenza A virus was found in 80 patients and the
influenza B virus in 20. The first positive specimen for
influenza was NPA in 84 patients and BAL in 16 (Table 1).
Seven patients diagnosed with NPA had a subsequent BAL in
the following days including 5 positive BAL. All of the 3 NPA
performed after diagnostic BAL were positive. The virus
was detected by direct immunofluorescence in 95 patients
and by viral culture in 5. Most (75%) of the patients were
admitted from November through February and half were
admitted during the last 3 study years.
All 100 patients presented with URTI and 53 progressed
to pneumonia (Fig. 1). Nineteen (19%) influenza infections
were nosocomial, with no significant difference across the
10-year study period. Time from symptom onset to diag-
nosis was 3 (2e6) days. The symptoms are listed in Table 1.
Fever was the most common symptom, with 88 patients. No
extrarespiratory influenza-related manifestations were
reported. The initial leukocyte count was 4.9 (2.8e
8.1)$109/L. PO2 at presentation was 65 (57e70) mm Hg withstudy patients with upper respiratory tract infection due to
tal NPAf BALg
(68%) 55 (55%) 13 (13%)
15 1
7 4
5 0
8 3
5 1
4 1
1 1
10 2
(11%) 10 (10%) 1 (1%)
(21%) 19 (19%) 2 (2%)
8 1
11 1
0 (100%) 84 (84%) 16 (16%)
(88%) 76 (76%) 12 (12%)
(71%) 61 (61%) 10 (10%)
(40%) 26 (26%) 14 (14%)
(27%) 24 (24%) 3 (3%)
(15%) 11 (11%) 4 (4%)
(11%) 10 (10%) 1 (1%)
ts displayed more than one symptom.
lasia, nZ 3.
on (nZ 8) or autoimmune nephropathy (nZ 1).
ructive pulmonary disease (nZ 5), or inflammatory nephropathy
Figure 1 Follow-up and outcomes of study patients.
Influenza in immunocompromised patients 1053a mean oxygen rate of 0 (0e3) L min1. All patients
underwent standard chest radiography. Table 2 depicts
radiographic patterns according to ICU admission and
outcome. All ICU patients had pulmonary infiltrates either
on chest radiographies or computed tomography (CT) scans.
None of the patients who died had normal chest radiog-
raphy at admission.
Associated infection was noted in 34 patients. The
associated infection was microbiologically documented in
16 patients and clinically documented in 18 patients. The
pathogens are shown in Table 3.
Hospital length of stay was 7 (2e17) days. Intensive care
unit (ICU) admission was required for 32 patients, who had
a median Simplified Acute Physiologic Score II (SAPS II) of 31(23e38). Of these 32 patients, 11 required mechanical
ventilation, 6 had shock, and 5 had acute renal failure. Ten
patients, all of them having pneumonia, died from non
resolving acute respiratory distress syndrome (ARDS) and ICU
acquired infections. Mortality was not influenced by the type
of underlying disease, HSCT recipient status, or type of
influenza virus. Mortality was higher in men than in women
(15% vs. 0%, PZ 0.036), in patients with nosocomial acqui-
sition of the influenza virus (26% vs. 6%, PZ 0.027), and in
patients with associated infection (24% vs. 3%, PZ 0.004).
Mechanical ventilation was associated with a 46% mortality
rate, compared to 6% in other patients (PZ 0.0003).
Factors significantly associated with pneumonia were
older age and infection with the influenza A virus (Table 4).
Table 2 Chest radiography characteristics according to ICU admission and mortality outcome.
Ward ICU p Alive Dead p
N 68 32 / 90 10 /
Normal 27 (40%) 10 (31%) 0.55 37 (41%) 0 (0%) 0.027
Bronchial thickening 11 (16%) 6 (19%) 0.06 17 (19%) 0 (0%) 0.23
Interstitial pattern 15 (22%) 6 (19%) 0.99 18 (20%) 5 (50%) 0.086
Lobar alveolar consolidation 18 (26.5%) 9 (28.5%) 0.04 23 (26%) 7 (70%) 0.01
Diffuse alveolar consolidation 2 (3%) 3 (9.5%) 0.32 4 (4.5%) 1 (10%) 0.99
Alveolar edema 1 (1.5%) 2 (6%) 0.44 3 (3%) 0 (0%) 0.99
Data are numbers (percent). Results are from univariate statistical analysis.
The sum of percentages may exceed 100% since some patients displayed more than one radiographic pattern on their chest
radiographies.
1054 D. Schnell et al.Pneumonia was not associated with the type of underlying
disease, season, or nosocomial acquisition. Dyspnea was
more common among patients with pneumonia (66% vs.
11%, P< 0.0001), but the other symptoms were not signif-
icantly different. Arterial oxygen saturation was lower in
patients with pneumonia (94% [91e96] vs. 100% [99e100],
P< 0.0001), who required higher oxygen rates (2 [0e6] vs.
0 [0e0] L min1, P< 0.0001). Associated infection was more
common among the patients with pneumonia (P< 0.0001).
By univariate analysis, influenza-related pneumonia was
associated with a longer hospital stay (5 [1e8.] vs 13 [6e
23], PZ 0.0002), higher need for mechanical ventilation
(21% vs. 0%, PZ 0.0028), and higher hospital mortality (19%
vs. 0%, PZ 0.005). By multivariate analysis, factors inde-
pendently associated with pneumonia were influenza A (OR
5.54, 95% CI [1.16e26.47]) and hematological malignancy
(OR 3.85, 95% CI [1.1e14.5]).
Nineteen patients received antiviral therapy (zanamivir
[Relenza, GlaxoSmithKline, Marly le Roi, France], nZ 7;
oseltamivir [Tamiflu, Roche, Neuilly sur Seine, France],
nZ 10; and ribavirin [Rebetol, Schering-Plough, Courbe-
voie, France], nZ 3) upon clinician’s request. One patient
received combination therapy with zanamivir and oselta-
mivir. Patients with and without antiviral therapy did not
differ regarding hypoxemia severity at presentation (PO2 at
admission 65 [56e70] mmHg for untreated patients vs 65.5Table 3 Associated infections and causative pathogens in patie
Total URTI alo
Associated infections 34 (34%) 4 (9%)
Clinically documented 18 (18%) 3 (7%)
Microbiologically documented 16 (16%) 1 (2%)
Bacterial infections 10 (10%) 0
Pseudomonas aeruginosa 3
Enterobacteriaceae 3
Haemophilus influenzae 3
Streptococcus pneumoniae 1
Fungal infections 4 (4%) 0
Aspergillus sp. 2
Fusarium sp. 1
Pneumocystis jirovecii 1
Viral infections 2 (2%) 1 (2%)
Respiratory syncytial virus 2 1
Data are numbers (percent). Results are from univariate statistical a
OR (95% CI): odds ratio (95% confidence interval).[61e94] mmHg, PZ 0.59) or pneumonia occurrence (56%
for untreated patients vs. 42%, PZ 0.42). Nevertheless,
mortality was significantly higher in the group given anti-
viral agents (26% vs. 6%, PZ 0.027).Discussion
In our cohort of 100 hospitalized immunocompromised
patients with influenza URTI, more than half progressed to
pneumonia, which was associated with a need for life-
supporting treatments, long hospital stays, and death.
Influenza A infection and hematological malignancies
independently predicted progression to pneumonia.
Strikingly, half the patients were diagnosed in the last 3
years, despite lower overall influenza activity than in earlier
study years (data from the Groupes Re´gionaux d’Observation
de la Grippe, available online at http://www.grog.org).
Patients enrolled over the last 3 years had similar clinical
presentation and outcome than other patients (data not
shown). This finding suggests improved diagnosis related to
increased physician awareness of the influenza burden in
immunocompromised patients and to the introduction of
a rapid diagnostic method suitable for use on noninvasive
respiratory sample. Thus, rapid antigen testing on NPA
provided the diagnosis in most of our patients.nts with and without pneumonia.
ne Pneumonia P value OR (95% CI)
30 (56%) <0.0001 14 (4.4e44.7)
15 (28%) 0.001 5.79 (1.56e21.5)
15 (28%) 0.0034 18.2 (2.29e144)
10 (19%) 0.019 /
3
3
3
1
4 (8%) 0.16 /
2
1
1
1 (1%) 0.99 0.89 (0.05e14.6)
1
nalysis.
Table 4 Comparison of patients with and without pneumonia.
No pneumonia Pneumonia P value OR (95% CI)
n 47 53
Agea 33 (13e51) 46 (36e63) 0.0033 1.03 (1.01e1.05)
Men/Women 31 (66%)/16 (34%) 34 (64%)/19 (36%) 0.99 0.92 (0.41e2.11)d
Influenza Ae 33 (70%) 47 (89%) 0.04 3.32 (1.16e9.52)
Seasonal acquisitionc 38 (81%) 37 (70%) 0.29 0.55 (0.22e1.39)
Nosocomial-acquired 8 (17%) 11 (21%) 0.83 1.28 (0.47e3.51)
Hematologic malignanciese 31 (66%) 37 (70%) 0.84 1.19 (0.52e2.77)
HSCT recipient 14 (30%) 20 (38%) 0.53 1.43 (0.62e3.29)
Neutropenia 2 (4%) 7 (13%) 0.43 2.55 (0.49e13.1)
Time from symptom onset
to diagnosisb
3 (2e5) 4 (2e6) 0.37 1.07 (0.94e1.22)
Dyspnea 5 (11%) 35 (66%) <0.0001 16.3 (5.5e48.5)
Associated infections 4 (9%) 30 (56%) <0.0001 14 (4.4e44.7)
Clinically documented 3 (7%) 15 (28%) 0.001 5.79 (1.56e21.5)
Microbiologically
documented
1 (2%) 15 (28%) 0.0034 18.2 (2.29e144)
Antiviral therapy 23% 15% 0.43 0.58 (0.21e1.6)
Length of hospital stayb 5 (1e8) 13 (6e23) 0.0002 1.02 (1.01e1.04)
Mechanical ventilation 0% 21% 0.0028 /
Hospital mortality 0% 19% 0.005 /
Data are numbers (percent) unless otherwise stated. Results are from univariate statistical analysis.
OR (95% CI): odds ratio (95% confidence interval).
a Years, median (quartile).
b Days, median (quartile).
c Infection occurring from November through February.
d Odds ratio and 95% confidence interval is given for men.
e By multivariate analysis, OR 5.54 (95% CI [1.16e26.47]) for influenza A and OR 3.85 (95% CI [1.1e14. 5]) for hematological
malignancies.
Influenza in immunocompromised patients 1055Influenza has been studied in patients with hematolog-
ical malignancies and in HSCT recipients,4e10 as well as in
HIV-infected patients.11e13 To our knowledge, this is the
first study of influenza in patients with immunosuppression
due to a variety of causes, including medications. In
patients with hematological malignancies and HSCT, the
rates of progression to pneumonia have ranged from less
than 10% to 80%.4e10 It was about 30% in the larger and
more recent studies,4e7 compared to 53% in our study. This
high pneumonia rate may have several explanations. First,
the retrospective study design may have introduced selec-
tion bias. Given the absence of universally accepted diag-
nostic criteria, screening for influenza may have been
performed preferentially in patients with greater disease
severity. However, the diagnostic strategy used routinely at
our institution for immunocompromised patients with
respiratory infections15 includes screening for respiratory
viruses, which limits selection bias. Little is known about
respiratory viral infections in patients with iatrogenic
immunosuppression. Nevertheless, in our study, the rate of
pneumonia in these patients e who contributed 21% of the
population e was not higher than in patients with other
causes of immunosuppression. Finally, circulating influenza
strains vary across geographic areas and from season to
season. Thus, differences in virulence across influenza
strains may contribute to differences in pneumonia rates.3
Among patients with pneumonia in our study, nearly 60%
had associated infection with at least one other organism.
Far lower rates, of 12% to 25%, were reported previously.5,7,9This higher rate is probably largely ascribable to the inclusion
of clinically documented cases of associated infection, in
addition to microbiologically documented associated infec-
tion, which occurred in only 28% of our patients. In immu-
nocompromised patients, pathogens responsible for
pneumonia are often difficult to recover, even by highly
invasive methods such as open lung biopsy,17 and empirical
treatment for respiratory pathogens is therefore often given
based on clinical and radiographic findings.15 Thus, including
these cases reflects clinical practice. Pseudomonas aerugi-
nosa and Enterobacteriaceae accounted for two-thirds of
documented bacteria, consistent with the chronic exposure
of our patients to the healthcare system.
All 10 patients who died in our study had pneumonia,
and the mortality rate among patients with pneumonia
(nZ 53) was 19%. Similarly, mortality rates ranged from
15% to 30% in earlier studies, and most of the patients who
died had pneumonia.4e7
By multivariate analysis, hematological malignancies and
influenza A infection independently predicted pneumonia.
The association of hematological malignancies with progres-
sion to pneumonia in multivariate but not in univariate anal-
ysis is quite surprising. Many confounders may have played
a role in these results. In several studies of hematological
patients with respiratory viral infections, lymphocytopenia
independently predicted progression to pneumonia.4e7 The
number of patients with missing lymphocyte counts at inclu-
sion inour studywas too large for this variable tobeentered in
our regression model. However, in our study, 80% of the
1056 D. Schnell et al.hematologic malignancies (54% of the population) were
diseases known to cause severe lymphocytopenia. To our
knowledge, our study is thefirst to identify influenzaAvirus as
a risk factor for progression topneumonia. Theexactmeaning
of this finding is unclear but may be consistent with the sus-
pected greater virulence of type A influenza strains.3,18
The effectiveness of antiviral agents in preventing
influenza-related pneumonia and death in immunocompro-
mised patients is unclear.7,19 In a recent study not specifically
focused on immunocompromised patients,20 neuraminidase
inhibitors were associated with a significant reduction in
mortality. About 20% of our study patients received antiviral
agents, usually neuraminidase inhibitors. The higher
mortality rate in these patients suggests that clinicians may
reserve antiviral agents for the sickest patients. Prospective
studies are needed to investigate the therapeutic benefits of
neuraminidase inhibitors in immunocompromised patients.
Our studyhas several limitations. The retrospective design
did not allow us to evaluate the incidence of influenza in our
study population and may have introduced, as discussed
above, a selection bias of the sicker patients. The number of
patients with HIV infection or iatrogenic immunosuppression
was too small for valid subgroup analyses. Conceivably,
patients with suspected or documented associated infection
might have had URTI due to influenza and pneumonia due to
the co-infecting organism. However, influenza is known to
promote bacterial and fungal superinfection of the lungs,3
suggesting that influenza played a key role in the develop-
ment of pneumonia. Immunization remains the cornerstone
of influenza prevention. Unfortunately, we could not recover
data on immunization status of our study patients.
In summary, influenza is an acute-onset febrile respira-
tory illness beginning with an URTI, occurring during the
winter months and in patients with profound lymphocytes
depletion. Pneumonia occurred in half the cases of
influenza-related URTI in our cohort of hospitalized immu-
nocompromised patients. Patients with hematological
malignancies or influenza type A infection were at
increased risk for pneumonia. Pneumonia was associated
with higher morbidity and mortality rates and with longer
hospital stays. Studies are warranted to evaluate the
benefits from antiviral therapy in these high-risk patients.
Acknowledgments
This study was supported by a grant from the Assistance-
Publique Hoˆpitaux de Paris [AOM 04139], a nonprofit institu-
tion. Assistance-Publique Hoˆpitaux de Paris was not involved
in study design, data collection and analysis, writing of the
manuscript and in the decision to submit it for publication.
Conflict of interest
No potential conflicts of interest occurred for any of the
authors.
Authors’ contribution to the study:
Study’s mentoring: Benoit Schlemmer and E´lie Azoulay
Study’s design, data collection and analysis: Catherine
Scieux, E´lie Azoulay, Je´roˆme Legoff and David Schnell.
Preparation and critical reviewing of the manuscript: all
authors.References
1. Beigel JH. Influenza. Crit Care Med 2008 Sep;36(9):2660e6.
2. Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K.
Systematic review and economic decision modelling for the
prevention and treatment of influenza A and B. Health Technol
Assess 2003;7(35):iiieiiv. xiexiii, 1e170.
3. Treanor J. Influenza virus. In: Mandell G, editor. Principles and
practice of infectious diseases. 5th ed. Philadelphia: Churchill
Livingston; 2000. p. 1823e49.
4. Ljungman P, Ward KN, Crooks BN, et al. Respiratory virus
infections after stem cell transplantation: a prospective study
from the Infectious Diseases Working Party of the European
Group for Blood and Marrow Transplantation. Bone Marrow
Transplant 2001 Sep;28(5):479e84.
5. Martino R, Ramila E, Rabella N, et al. Respiratory virus infec-
tions in adults with hematologic malignancies: a prospective
study. Clin Infect Dis 2003 Jan 1;36(1):1e8.
6. Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infec-
tions after hematopoietic stem cell transplantation: risk
factors, mortality, and the effect of antiviral therapy. Clin
Infect Dis 2004 Nov 1;39(9):1300e6.
7. Chemaly RF, Ghosh S, Bodey GP, et al. Respiratory viral
infections in adults with hematologic malignancies and human
stem cell transplantation recipients: a retrospective study at
a major cancer center. Medicine (Baltimore) 2006 Sep;85(5):
278e87.
8. Whimbey E, Elting LS, Couch RB, et al. Influenza A virus
infections among hospitalized adult bone marrow transplant
recipients. Bone Marrow Transplant 1994 Apr;13(4):437e40.
9. Yousuf HM, Englund J, Couch R, et al. Influenza among hospi-
talized adults with leukemia. Clin Infect Dis 1997 Jun;24(6):
1095e9.
10. Machado CM, Boas LS, Mendes AV, et al. Low mortality rates
related to respiratory virus infections after bone marrow trans-
plantation. Bone Marrow Transplant 2003 Apr;31(8):695e700.
11. Safrin S, Rush JD, Mills J. Influenza in patients with human
immunodeficiency virus infection. Chest 1990 Jul;98(1):33e7.
12. Neuzil KM, Reed GW, Mitchel Jr EF, Griffin MR. Influenza-
associated morbidity and mortality in young and middle-aged
women. JAMA 1999 Mar 10;281(10):901e7.
13. Klein MB, Lu Y, DelBalso L, Cote S, Boivin G. Influenzavirus
infection is a primary cause of febrile respiratory illness in HIV-
infected adults, despite vaccination. Clin Infect Dis 2007 Jul
15;45(2):234e40.
14. Azoulay E, Mokart D, Rabbat A, et al. Diagnostic bronchoscopy
in hematology and oncology patients with acute respiratory
failure: prospective multicenter data. Crit Care Med 2008 Jan;
36(1):100e7.
15. Azoulay E, Schlemmer B. Diagnostic strategy in cancer patients
with acute respiratory failure. Intensive Care Med 2006 Jun;
32(6):808e22.
16. Rano A, Agusti C, Jimenez P, et al. Pulmonary infiltrates in non-
HIV immunocompromised patients: a diagnostic approach using
non-invasive and bronchoscopic procedures. Thorax 2001 May;
56(5):379e87.
17. Hiatt JR, Gong H, Mulder DG, Ramming KP. The value of open
lung biopsy in the immunosuppressed patient. Surgery 1982
Aug;92(2):285e91.
18. Baine WB, Luby JP, Martin SM. Severe illness with influenza B.
Am J Med 1980 Feb;68(2):181e9.
19. Machado CM, Boas LS, Mendes AV, et al. Use of Oseltamivir to
control influenza complications after bone marrow trans-
plantation. Bone Marrow Transplant 2004 Jul;34(2):111e4.
20. McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and
outcomes of influenza requiring hospitalization in Ontario,
Canada. Clin Infect Dis 2007 Dec 15;45(12):1568e75.
